Immunotherapy duo takes on rare cancers
NCT ID NCT04969887
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink or control rare cancers that are known to respond to immunotherapy. The study includes 240 people with advanced biliary tract, neuroendocrine, gynecologic, or MSI-H solid tumors (excluding colorectal cancer). Researchers aim to confirm the clinical benefit seen in an earlier study and measure how long patients live without their cancer growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ipilimumab and nivolumab (immune checkpoint inhibitors)
- What this could lead to
- If successful, this could provide an effective treatment option for several rare cancers that currently have limited therapies.
- What could go wrong
- This is a Phase 2 trial with a moderate number of participants, so results may not confirm benefit. Immune-related side effects from these drugs can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Auckland City Hospital
Auckland, New Zealand
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
Barwon Health
Geelong, Victoria, Australia
-
Bendigo Health Services
Bendigo, Victoria, Australia
-
Blacktown Hospital
Sydney, New South Wales, 2145, Australia
-
Border Medical Oncology Unit
Albury, New South Wales, 2640, Australia
-
Cairns and Hinterland Hospital and Health Service
Cairns, Queensland, 4870, Australia
-
Calvary Mater Newcastle
Waratah, New South Wales, 2298, Australia
-
Fiona Stanley Hospital
Perth, Western Australia, Australia
-
Goulburn Valley Health
Shepparton, Victoria, 3630, Australia
-
Orange Health Service
Orange, New South Wales, Australia
-
Peninsula Health
Frankston, Victoria, Australia
-
Peter MacCalllum Cancer Centre
Parkville, Victoria, Australia
-
Royal Adelaide Hospital
Adelaide, South Australia, Australia
-
Royal Hobart Hospital
Hobart, Tasmania, 7000, Australia
-
South West Healthcare
Warrnambool, Victoria, Australia
-
Townsville Hospital and Health Service
Douglas, Queensland, 4814, Australia
-
Townville Hospital and Health Service
Townsville, Queensland, 4814, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Can a targeted antibody boost chemotherapy for a rare bile duct cancer?
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New camera could make cancer treatment safer by better tracking radiation